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BACKGROUND: Advanced glycation end products (AGE) and their receptor (RAGE) system play an important role in the development of diabetic 
vascular complications. Recently, an endogenous secretory 
RAGE (esRAGE) has been identified as a novel splice 
variant, which lacks the transmembrane domain and is 
secreted in human sera. Interestingly, it was reported that 
esRAGE binds AGE ligands and neutralizes AGE actions. 
Many studies have reported that diabetes mellitus correlates 
with vascular calcification event and increases progressively 
in uncontrolled diabetes. Matrix Gla Protein (MGP) is known 
to act as an inhibitor in vascular calcification. The aim of 
this study was to observe progress of vascular calcification 
in uncontrolled diabetes patient by biochemical markers 
MGP as inhibitor in vascular calcification, via mechanism 
of AGEs.
METHODS: This study was an observational study with 
cross sectional design on adult type 2 diabetic male patients 
who were defined by the 2011 Indonesian diabetes mellitus 
consensus criteria.
RESULTS: The results of this study showed that there 
was a positive significant correlation between esRAGE 
and HbA1C (r=0.651, p=0.009), and negative correlation 
between MGP and HbA1C (r=-0.465, p=0.081) in 
controlled diabetes group. In uncontrolled diabetes group 
there was a positive significant correlation between MGP 
and HbA1C (r=0.350, p=0.023), despite the fact esRAGE 
showed no significant correlation with HbA1C. There was 
no significant difference in level of esRAGE and MGP 
in controlled and uncontrolled diabetes group, but MGP 
LATAR BELAKANG: Advanced glycation end products (AGE) dan reseptornya (RAGE) berperan penting dalam perkembangan komplikasi 
pada diabetes. Penelitian terkini mendapatkan bahwa 
endogenous secretory RAGE (esRAGE) merupakan varian 
baru dari RAGE akibat mutasi sehingga kehilangan area 
transmembrannya, sehingga bisa ditemukan di serum. 
Menariknya, telah ditemukan bahwa esRAGE mengikat 
ligan dari AGE dan menetralkan aktivitas dari AGE. Banyak 
studi melaporkan bahwa diabetes melitus berhubungan 
dengan kejadian kalsifikasi vaskular, dan progresifitasnya 
meningkat pada diabetes yang tidak terkontrol. Matrix 
Gla Protein (MGP) diketahui merupakan molekul yang 
bertindak sebagai inhibititor kalsifikasi vaskular. Tujuan 
dari penelitian ini adalah untuk mengetahui progresifitas 
kalsifikasi vaskular pada pasien diabetes melitus yang 
tidak terkontrol melalui MGP sebagai inhibitor kalsifikasi, 
melalui mekanisme yang melibatkan AGE.
METODE: Penelitian ini merupakan studi observasi 
dengan desain potong lintang pada pria dewasa dengan 
diabetes melitus tipe 2 sesuai kriteria konsensus diabetes 
melitus Indonesia 2011.
HASIL: Hasil dari penelitian ini menunjukkan bahwa 
ada korelasi positif yang signifikan antara esRAGE and 
HbA1C (r=0,651, p=0,009), dan korelasi negatif antara 
MGP and HbA1C (r=-0,465, p=0,081) pada kelompok 
diabetes terkontrol. Pada kelompok yang tidak terkontrol, 
ada korelasi positif yang signifikan antara MGP and HbA1C 
(r=0,350, p=0,023), sementara esRAGE tidak menunjukkan 
adanya korelasi yang signifikan dengan HbA1c. Tidak 
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According to the WHO survey, Indonesia ranks fourth of 
all countries in the world in the number of patients with 
diabetes mellitus (DM) with a prevalence of about 8.6% 
of the total population. Another fact is the data from the 
Ministry of Health, which state that the number of inpatients 
and outpatients in hospitals with diabetes is ranked first 
of all endocrine diseases. Worldwide, the incidence of 
type 2 diabetes mellitus (T2DM) is increasing rapidly. In 
Indonesia, WHO estimates the increasing number of people 
with diabetes may rise from 8.4 million in 2000  may rise to 
about 21.3 million by 2030.(1)
 Two main subtypes of diabetes are type 1 and T2DM. 
T2DM comprises about 80-90% of all cases.(2) Diabetic 
patients may suffer a number of debilitating complications 
such as retinopathy, nephropathy, neuropathy, and 
atherosclerosis resulting in cardiovascular, cerebrovascular, 
or peripheral vascular disease. These diabetic complications 
lead to huge economic and psychosocial consequences.(3)
 Diabetes mellitus, particularly T2DM, is associated 
with a markedly increased risk of cardiovascular events 
mainly due to premature and extensive atherosclerosis. (2)
 There are several mechanisms that underlie the 
occurrence of complications in diabetes, one of which 
is the formation of advanced glycation end products 
(AGE). By generating oxidative stress, AGE encourages 
vasoconstriction, inflammatory and prothrombotic gene 
expression, which would result in endothelial dysfunction.
(4) This causes damage to the retina, the nephrons, the central 
and peripheral nervous system, as well as atherosclerosis.
(5) Some receptors for AGE have been found, one of which 
showed lower level in uncontrolled diabetes group, contrary 
to esRAGE that had higher concentration.
CONCLUSION: In diabetes condition, complications 
of vascular calcification are caused by the mechanism 
of increased AGE formation  represented by esRAGE. 
In diabetes control it is very important to keep the blood 
vessels from complications caused by vascular calcification.
KEYWORDS: type 2 diabetes mellitus, vascular 
calcification, esRAGE, MGP, HbA1C
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ditemukan adanya perbedaan yang signifikan kadar esRAGE 
dan MGP baik pada kelompok diabetes terkontrol maupun 
tidak terkontrol, tetapi kadar MGP ditemukan lebih rendah 
pada kelompok diabetes tidak terkontrol, sebaliknya kadar 
esRAGE ditemukan lebih tinggi.
KESIMPULAN: Pada kondisi diabetes, komplikasi 
kalsifikasi vaskular salah satunya disebabkan mekanisme 
peningkatan AGE yang direpresentasikan oleh esRAGE. 
Pada kondisi diabetes, pengontrolan kadar gula darah sangat 
diperlukan untuk menjaga pembuluh darah dari komplikasi 
yang disebabkan oleh kalsifikasi vaskular.
KATA KUNCI: diabetes melitus tipe 2, kalsifikasi vaskular, 
esRAGE, MGP, HbA1C
is the receptor for AGE (RAGE), which is a key component 
of the amplification of the inflammatory cascade and tissue 
injury constantly(4). RAGE has an isoform called soluble 
RAGE (sRAGE), Endogenous secretory RAGE (es-RAGE), 
a splice variant of one of the naturally occurring secretory 
forms, is known to carry all the extracellular domains 
but lacks the transmembrane and cytoplasmic domains. 
Secreted es-RAGE in the extracellular space is thought 
to act as a decoy receptor that binds AGEs and results in 
reducing the activity of intercellular signal pathways via 
RAGE.(6) Atherosclerotic disease is characterized by the 
accumulation of lipid material in the arterial wall resulting 
from autoimmune and inflammatory mechanisms. More 
than 90% of these fatty plaques undergo calcification. Some 
studies have demonstrated a direct relationship between 
the degree of calcification of the atherosclerotic plaque and 
mortality due to cardiovascular events.(7)
 Vascular calcification, long a result of passive 
degeneration, involves a complex, regulated process of 
biomineralization resembling osteogenesis. Evidence 
indicates that proteins controlling bone mineralization are 
also involved in the regulation of vascular calcification. 
Vascular calcification is exacerbated in certain clinical 
entities, including diabetes, menopause, and osteoporosis.
(8)
 In patients with diabetes, arterial calcification 
is associated with an increased risk of cardiovascular 
complications.(9) In sub-sample of the population-based 
Framingham Offspring Study, subjects with insulin 
resistance or impaired fasting glucose (IFG) / impaired 
glucose tolerance (IGT) and T2DM had an increased burden 
of coronary artery subclinical atherosclerosis, shown by 
using Electron-Beam Computed Tomography(10).
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 Recent data suggest that arterial calcifications occur 
as the result of an active, regulated process that involves 
inhibitors and promoters of vascular calcification. This 
idea is based partly on findings of high expression of bone-
related macromolecules, such as alkaline phosphatase, 
bone sialoprotein, bone Gla protein and osteoprotegerin as 
promoters of calcification in calcified areas of the arterial 
wall. Furthermore, direct evidence comes from gene 
knockout experiments of matrix Gla protein (MGP) and 
osteopontin-lacking mice, which develop extensive vascular 
calcification.(11,12)
 MGP is inhibitor of vascular calcification involved 
in the development of DM complication, especially 
uncontrolled diabetes. This inspired us to study the difference 
of vascular calcification event between controlled and 
uncontrolled T2DM. The aim of this study was to observe 
the progress of vascular calcification in diabetic patients by 
mechanism of esRAGE, and biochemical marker MGP as 
inhibitor in vascular calcification among Indonesian T2DM 
male patients.
Assay of Biochemical Markers  
Blood specimen was collected by venipuncture in serum 
tubes (10 mL; BD Vacutainer Systems) and in sodium 
citrate (10 mL; BD Vacutainer Systems) and stored for 20 
minutes at room temperature before centrifugation. Serum 
and plasma were sub-sampled in aliquots and frozen at 
-20°C.
 Serum MGP concentrations were quantified with the 
kit from Biomedica (Vienna, Austria). The kit is based on the 
competitive enzyme-linked immunosorbent assay (ELISA) 
principle with antibodies against non-phosphorylated MGP 
coated on the microtiter plate.
 Serum esRAGE concentrations were quantified 
with the kit from B-Bridge International Human esRAGE 
ELISA. The kit is based on the sandwich ELISA principle. 
This assay employs an antibody specific for human esRAGE 
coated on a 96-well plate.
 All assays were performed according to manufacturers’ 
instruction.
Statistical Analysis
Statistical analysis was performed with the SPSS 11.5 
statistical software package. Univariate analysis was 
performed to calculate mean, maximum and minimum 
value and SD. Spearman correlation statistic was used to 
determine the correlation among the various variables. 
Significance levels were based on two-tailed tests.
The study protocol was approved with ethical clearance 
obtained from the Health Research Ethics Committee 
Faculty of Medicine, University of Hasanuddin, Makassar, 
Indonesia. All participants signed written informed consent.
 Sixty one T2DM male patients were enrolled in this 
cross sectional study.  At the baseline examination, each 
participant completed a self administered questionnaire 
covering medical history, exercise, treatment for hypertension 
or diabetes, smoking habits, and alcohol intake. The 
questionnaire was checked by researcher at the screening. 
Subjects who were consuming steroid; or had been treated 
with anti-inflammatory drugs such as statins in the last 3 
weeks; or had liver dysfunction, kidney dysfunction, fever 
and other acute inflammation were excluded from the study. 
Each subject was given explanation about the study and 
asked to sign informed consent prior to the commencement 
of the study.
 All subjects were assessed after overnight fasting 
for at least 10 hours. The parameters of anthropometric 
measurements (height, weight, body mass index (BMI), 
waist circumference, and blood pressure) and the 
biochemical variables (fasting plasma glucose (FPG), 
estimated Glomerular Filtration Rate (eGFR), Alanine 
transaminase (ALT),  glycated hemoglobin / hemoglobin 
A1c (HbA1c), MGP) were measured in all subjects.
Most of Subjects are poorly controlled DM 
Statistical tests in this study were performed on 61 subjects, 
which consisted of 17 subjects with controlled DM (HbA1c 
<7%) and 44 subjects with poorly controlled DM (HbA1c 
>7%). eGFR values for renal function and ALT values for 
liver function of the 61 subjects were within normal limits. 
General description of subject’s baseline characteristics  is 
shown in Table 1.
Table 1.  Subjects’ Baseline Characteristics.
Variables Min Max Mean SD
Age (years) 36 63 53.40 6.70
Clinical Variables
BMI 14.90 33.50 23.71 3.18
Biochemical Variables
FPG (mg/dl) 55 294 143.50 50.50
HbA1c (%) 5.10 12.60 8.30 1.90
esRAGE (ng/ml) 0.08 0.90 0.34 0.15
MGP (nmol/l) 52,056 194,878 109,508 31,987
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Correlation between HbA1c with esRAGE and MGP
Table 2 shows the correlation between HbA1c and esRAGE 
and inhibitor of vascular calcification in controlled and 
uncontrolled T2DM groups. The trend is  shown in Figure 
1 and 2.
Inhibitor of Vascular Calcification is lower in 
Uncontrolled T2DM Group
To see the difference in esRAGE and inhibitor of vascular 
calcification between controlled T2DM and uncontrolled 
T2DM groups, an independent t-test was done and the result 
showed the existence of differences, but not significant. 
The concentration of esRAGE in uncontrolled T2DM 
group was higher than that in controlled T2DM group, 
but in the contrary the concentration of MGP was lower in 
uncontrolled T2DM. These results are shown in Table 3.
The results of this study showed in controlled T2DM group 
there was a positive significant correlation between HbA1c 
with esRAGE levels, and there was no significant correlation 
in uncontrolled T2DM group, meaning that esRAGE was 
closely related to well-controlled diabetic condition.
 The balance between the levels of RAGE ligands, 
RAGE and sRAGE may represent a dynamic system. It 
has been demonstrated that pathophysiological situations 
of DM enhance the expression of RAGE and its ligands. 
Inflammation increases the production and accumulation of 
AGEs, and subsequently leads to the increased activation 
of RAGE and further enhances the inflammatory state. The 
relationship between the up-regulation of RAGE/RAGE 
ligands and the level of ‘protective’ sRAGE levels is of 
obvious clinical interest. On the other hand, in vitro studies 
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Figure 3. Comparison of serum levels of MGP among controlled 
and uncontrolled T2DM groups.
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Figure 1. Plasma esRAGE according to the plasma HbA1C.
Figure 2. Plasma MGP according to the plasma HbA1C.
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Table 2. Correlation between HbA1c with esRAGE and MGP 
in controlled and uncontrolled T2DM groups.
* = significant at p<0.05
r p r p
esRAGE 0.651* 0.009 0.010 0.950
MGP -0.465* 0.081 0.350* 0.023
HbA1c
Controlled T2DM 
Group (n=13)
Uncontrolled T2DM 
Group (n=40)
Variable
Table 3. T-test analysis of esRAGE and MGP in controlled and 
uncontrolled T2DM groups
Variables
Controlled 
T2DM Group
Uncontrolled 
T2DM Group p
esRAGE (ng/ml) 0.309±0.104 0.350±0.172 0.584
MGP (nmol/l) 112,170±26,155 108,479±34,183 0.426
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recently revealed that treatment of cells with High mobility 
group protein B1 (HMGB1) increased the formation of 
soluble cRAGE released in the supernatant. Similarly, a 
positive correlation between serum AGEs and sRAGE levels 
in non-diabetic subjects has been highlighted, suggesting 
that interaction of RAGE with its ligands enhances sRAGE 
synthesis. However, sRAGE has been shown to have a 
negative feedback on RAGE interaction with its ligands. 
Therefore it seems that sRAGE, RAGE and its ligands 
are three elements of a balance with positive and negative 
feedbacks which could be modified by pathophysiological 
situations. The precise mechanisms responsible for the fine 
balance between membrane-bound RAGE and its secreted/
cleaved soluble variant are currently unknown, and the 
elucidation of the mechanism(s) responsible for their 
regulation is an important biological question.(13) This 
study showed that in controlled T2DM group there was 
a negative correlation between HbA1c with MGP levels 
although not statistically significant, and the serum level 
of MGP as inhibitor of vascular calcification was lower in 
uncontrolled diabetes group although this difference was not 
statistically significant, it means that subjects with diabetes 
have a risk for vascular calcification.
 Supporting this notion, recent reports have suggested 
a sequence of molecular events in vascular calcification 
beginning with the loss of expression by by vascular smooth 
muscle cells (VSMCs), of constitutive inhibitory proteins, 
and ending with expression by VSMCs and macrophages 
of chondrocytic, osteoblastic, and osteoclastic-associated 
proteins that orchestrate the calcification process.(14)
 Vascular calcification is a consequence of tightly 
regulated processes that culminate in organized extracellular 
matrix deposition by osteoblast-like cells. These cells may 
be derived from stem cells or differentiation of existing 
cells, such as smooth muscle cells or pericytes. Several 
factors induce this transition, including bone morphogenetic 
proteins, oxidant stress, high phosphate levels, parathyroid 
hormone fragments, and vitamin D. Once the osteogenic 
phenotype is induced, cells gain a distinctive molecular 
fingerprint, marked by the transcription factor core binding 
factor 1. Alternatively, loss of inhibitors of mineralization, 
such as matrix carboxyglutamic acid Gla protein, fetuin, 
and osteopontin, also contribute to vascular calcification.
(14)
 The result of this study also showed a positive 
significant correlation between HbA1c with MGP levels 
in uncontrolled T2DM group. Why are greater MGP levels 
in humans associated with diabetes and with an increased, 
rather than a decreased, risk of cardiovascular disease? 
One hypothesis is that increased serum MGP levels in 
In diabetes condition, complication of vascular calcification 
are caused by the mechanism of increased AGE formation, 
represented by esRAGE. In diabetes control it is very 
important to keep the blood vessels from complication 
caused by vascular calcification.
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